# AngalBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angalbio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.angalbio.com/
- Latest round: Series A (Apr 29, 2026)
- Investors on record: 1

## About

Based in Suzhou, China and founded in 2019, Angal Biotechnologies Ltd., trading under the name AngalBio, focuses on biopharmaceutical research and development. In April 2026, the company raised a Series A funding round led by Suzhou Hi-Tech Angel Venture Capital Management.

The company works with research institutions and healthcare partners to develop biopharmaceutical therapies. Its pipeline includes antisense oligonucleotide candidates targeting specific genetic markers, with applications in diseases such as glioblastoma. The company also engages in licensing and technology transfer collaborations to advance drug development programs.

The company generates revenue through licensing agreements and partnerships, including upfront payments and milestone-based royalties linked to the development and commercialization of its drug candidates.

The company plans to use the latest funding to expand its R&D team, upgrade its technology platforms, and advance the progression of its new drug pipelines.

## Funding rounds

- Series A, Apr 29, 2026 — Suzhou Hi-Tech Angel Venture Capital Management

## Investors

- Suzhou Hi-Tech Angel Venture Capital Management (https://capitalatlas.ai/funds/suzhou-hi-tech-angel-venture-capital-management) — Series A